¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Are Self-Expandable Valves a Valid Option in Bicuspids?

Bicuspid Aortic Valves (VAV) are challenging for TAVR given its anatomical characteristics and the important presence of calcification. However, current data are promising.  Even though traditionally excluded from the larger randomized studies, self-expandable valves appear to have similar evolution to tricuspid aortic valves (TAV) with severe stenosis.  Researchers looked at the Low-Risk Bicuspid Study and<a href="https://solaci.org/en/2022/03/16/are-self-expandable-valves-a-valid-option-in-bicuspids/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

Are Expandable-Balloon Valves an Option for the Bicuspid Valve in Low-Risk Patients?

Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Prosthesis-Annular Size Ratio and Its Impact on Leaks

In low-risk patients, there was a very low incidence of greater than moderate leak, including in patients with minimal oversizing. The degree of prosthesis oversizing had a great impact on mild paravalvular leak reduction and the need for post-dilation without changing valve hemodynamics. This research investigated the impact of the perimeter and the area, measured<a href="https://solaci.org/en/2021/12/03/prosthesis-annular-size-ratio-and-its-impact-on-leaks/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version.  In this regard, below you will find what has been called “10 commandments” that sum up this new document, to keep you in the loop.  The incidence<a href="https://solaci.org/en/2021/11/29/ten-commandments-for-2021-guidelines-on-valvular-heart-disease/" title="Read more" >...</a>

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5 days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

$hipertensión refractaria$

Hypertensive Patients: Maximizing Doses or Adding New Drugs

Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes costs, among other advantages.  On the flipside, patients having to remember a whole list of drugs and their combination will often lead to non-adherence or forgetfulness. The latter has been shown not only by dedicated trials, but also<a href="https://solaci.org/en/2021/10/14/hypertensive-patients-maximizing-doses-or-adding-new-drugs/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>

ESC 2021 | Novedades de las nuevas guías de valvulopatías de la Sociedad Europea de Cardiología

ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease

Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease.  This new document was<a href="https://solaci.org/en/2021/09/09/esc-2021-updated-european-society-of-cardiology-guidelines-for-the-management-of-valvular-heart-disease/" title="Read more" >...</a>

37th Annual Meeting of the Uruguayan Society of Cardiology: Registration Waiver for SOLACI Members!

The 37° Annual Meeting of the Uruguayan Society of Cardiology, to be held virtually from May 26 thru 28 by the Uruguayan Society of Cardiology (SUC), is of the highest academic and scientific value.  The event will have relevant international guests and will run through different topics, such as atrial fibrillation, chronic coronary syndromes, type<a href="https://solaci.org/en/2021/05/21/37th-annual-meeting-of-the-uruguayan-society-of-cardiology-registration-waiver-for-solaci-members/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>